Expert US stock capital allocation track record and investment grade assessment for management quality evaluation. We evaluate how well management has historically deployed capital to create shareholder value.
As of 2026-04-08, Keros Therapeutics Inc. (KROS) is trading at a current price of $12.5, marking a 2.12% gain on the day. This analysis examines key technical levels, recent market context, and potential future scenarios for the biotech stock, with no recent earnings data available for the company as of this publication. KROS has seen relatively range-bound trading in recent weeks, with price action largely tied to broader biotech sector flows rather than company-specific news. Key takeaways for
Is Keros Therapeutics (KROS) Stock heavily shorted | Price at $12.50, Up 2.12% - Money Flow
KROS - Stock Analysis
4415 Comments
1829 Likes
1
Emyleigh
Engaged Reader
2 hours ago
This kind of delay always costs something.
π 69
Reply
2
Nikina
Daily Reader
5 hours ago
Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying specific stocks in the market. We monitor 13F filings and institutional buying patterns because large investors often have superior information and research capabilities. We provide ownership data, fund flow analysis, and institutional positioning for comprehensive coverage. Follow institutional money with our comprehensive ownership tracking and analysis tools for smarter investment decisions.
π 256
Reply
3
Shonn
New Visitor
1 day ago
Really helpful breakdown, thanks for sharing!
π 89
Reply
4
Kawika
Legendary User
1 day ago
US stock options flow analysis and unusual options activity tracking to identify smart money positions in the market. Our options intelligence reveals hidden bets and sentiment indicators that often precede major price moves.
π 46
Reply
5
Verinda
Consistent User
2 days ago
A cautious rally suggests investors are balancing risk and reward.
π 38
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.